NVX-108 is under clinical development by NuvOx Pharma and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Glioblastoma Multiforme (GBM) have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NVX-108’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NVX-108 overview

NVX-108 is under development for the treatment of glioblastoma multiforme. It is administered through intravenous route. The drug candidate is an emulsion of 2 percent w/v dodecafluoropentane (DDFP) stabilized by surfactant in a buffered sucrose solution. It was also under development for the treatment of hemorrhagic shock, prostate cancer, pancreatic cancer, hepatoma and traumatic brain injury. The drug candidate is a radiation sensitizer.

NuvOx Pharma overview

NuvOx Pharma is a biotechnology company that develops oxygen therapeutics for the treatment of hypoxia related diseases. The company’s product pipeline includes NVX-208, a drug being developed against strokes. It also designs medicines for treating cancers, sickle cell crises, traumatic brain injury, myocardial infarction and hemorrhagic shocks. The company develops therapies and formulations based on dodecafluoropentane emulsion (DDFPe) platform, a novel nanotechnology for oxygen delivery. NuvOx Pharma is headquartered in Tucson, Arizona, the US.

For a complete picture of NVX-108’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.